# Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma

> **NCT04958486** · EARLY_PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 4 (actual)

## Conditions studied

- Fossa Ependymoma

## Interventions

- **DRUG:** 5-Azacytidine and trastuzumab infusion

## Key facts

- **NCT ID:** NCT04958486
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-09-29
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04958486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04958486, "Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04958486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*